Abbott vs. Intuitive Surgical: Best MedTech Stock for 2024
Two medtech giants go head-to-head. Here's which offers stronger long-term upside for investors.
Two of the most closely watched names in medical technology — Abbott Laboratories and Intuitive Surgical — are drawing fresh scrutiny from investors seeking durable, long-term growth in a sector known for both innovation and resilience. The core question: which company is better positioned to deliver sustained shareholder value over the coming years?
Abbott brings diversification to the table, operating across diagnostics, medical devices, nutrition, and established pharmaceuticals. That breadth has historically served as a buffer during economic downturns, giving the company multiple revenue engines to lean on when any single segment faces pressure. Intuitive Surgical, by contrast, is a more concentrated bet — one built almost entirely around its da Vinci robotic surgery platform, a system that has become deeply embedded in hospital operating rooms worldwide.
Read more Jim Cramer's 20% Rule for Picking Winning Stocks Explained →
The bull case for Intuitive Surgical centers on the recurring revenue generated by instrument and accessory sales tied to each installed da Vinci system. Every new robot placed in a hospital creates a long-term consumables stream, making the business model increasingly predictable as its global install base expands. Abbott's appeal, meanwhile, lies partly in its FreeStyle Libre continuous glucose monitoring franchise, which continues to capture market share in the fast-growing diabetes management space.
From a valuation standpoint, Intuitive Surgical typically commands a premium multiple relative to the broader medtech sector, reflecting investor confidence in its competitive moat and growth runway. Abbott, trading at a comparatively more modest valuation, may appeal to investors who prioritize balance between growth and income, given the company's long history of dividend payments. Risk tolerance and investment horizon will ultimately shape which stock fits a given portfolio better.
Both companies operate in a sector tailwinds-rich environment driven by aging populations, rising global healthcare spending, and accelerating adoption of minimally invasive procedures. Continue reading at Yahoo Finance.
